Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.32 |
| ▸ | SCN4A | P35499 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031393 | 0.80 | ANPEP (0.38) | MAOAPTGS1LMNACA4ANPEP | |
| SCHEMBL3894413 | 0.80 | CA4 (0.36) | MAOAPTGS1LMNACA4TAAR1 | |
| SCHEMBL51246 | 0.71 | LTA4H (0.50) | MAOALMNACA4TAAR1LTA4H | |
| SCHEMBL16534280 | 0.69 | LTA4H (0.47) | MAOALMNACA4TAAR1LTA4H | |
| SCHEMBL29965221 | 0.69 | LTA4H (0.47) | MAOALMNACA4TAAR1LTA4H | |
| Methane SCHEMBL29002032 | 0.69 | LTA4H (0.47) | MAOALMNACA4TAAR1LTA4H | |
| Ammonia Solution, Strong SCHEMBL28193113 | 0.69 | LTA4H (0.47) | MAOALMNACA4TAAR1LTA4H | |
| SCHEMBL10777066 | 0.69 | LTA4H (0.47) | MAOALMNACA4TAAR1LTA4H | |
| Hydrogen Sulfide SCHEMBL16338972 | 0.69 | LTA4H (0.47) | MAOALMNACA4TAAR1LTA4H | |
| SCHEMBL4398278 | 0.69 | LTA4H (0.47) | MAOALMNACA4TAAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | claimed |
| WO-2012012498-A9 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| WO-2012012498-A2 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| WO-2004042021-A2 | METHOD FOR INHIBITING CALCIUM-INDUCED CELL DEATH | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2004-05-21 | — | — | WO | claimed |
| US-20240156728-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX OPERATING CO INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4008326-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | Pulmatrix Operating Company, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11173115-B2 | Monovalent metal cation dry powders for inhalation | PULMATRIX OPERATING COMPANY, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3470057-B1 | CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT | PULMATRIX OPERATING CO INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210121399-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX OPERATING COMPANY, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20210060268-A1 | INHALABLE DRY POWDERS | PULMATRIX OPERATING COMPANY, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10806871-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2012012498-A9 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044736-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012012498-A2 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20100062437-A1 | PARALLEL PROFILLING OF SIGNALING PATHWAYS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2010-03-11 | — | — | US | disclosed |
| CN-101610789-A | Methods, compositions and kits for treating pain and itch | HARVARD COLLEGE (US) | 2009-12-23 | — | — | CN | disclosed |
| WO-2004042021-A3 | METHOD FOR INHIBITING CALCIUM-INDUCED CELL DEATH | UNIV MARYLAND (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2004042021-A2 | METHOD FOR INHIBITING CALCIUM-INDUCED CELL DEATH | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004042021-A2 | METHOD FOR INHIBITING CALCIUM-INDUCED CELL DEATH | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | TRPV1, TRPC4, TRPC3 | MAOA 875/4885PTGS1 462/4885LMNA 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.